00:27 , Aug 2, 2019 |  BC Innovations  |  Distillery Therapeutics

Gut microbe to reduce ALS severity

DISEASE CATEGORY: Neurology INDICATION: Amyotrophic lateral sclerosis (ALS) Co-founders and collaborators of DayTwo Ltd. and BiomX Ltd. showed that oral administration of the nicotinamide biosynthesizing gut microbiome species A. muciniphila could slow ALS progression. Compared...
22:20 , Aug 1, 2019 |  BC Innovations  |  Translation in Brief

Making connections between ALS and gut microbes

Israeli researchers have linked gut microbiome species and metabolic pathways to ALS and shown that different species can ameliorate or exacerbate disease. The microbiome and gut-brain axis have increasingly been implicated in neurological disorders including...
21:34 , Jul 26, 2019 |  BC Extra  |  Preclinical News

July 26 preclinical Quick Takes: Ribon's new mechanism for PARP inhibitors, a microbiome-ALS link and more

Ribon co-founder reports new mechanism for PARP inhibitors   An University of Texas Southwestern team led by Ribon Therapeutics Inc. (Lexington, Mass.) co-founder W. Lee Kraus reported that PARP inhibitors block ribosome production, and therefore...
23:01 , Jul 17, 2019 |  BC Extra  |  Company News

July 17 Company Quick Takes: FDA approves Merck antibiotic combo; plus PureTech, Inovio, BiomX

FDA approves Merck's antibiotic combo  FDA approved Merck's Recarbrio imipenem/cilastatin/relebactam antibacterial to treat adults with complicated urinary tract infections (cUTIs) and complicated intra-abdominal infections (cIAIs). Unlike most of its peers, Merck & Co. Inc. (NYSE:MRK)...
23:50 , Jun 11, 2019 |  BC Extra  |  Company News

June 11 Company Quick Takes: Genmab, Janssen together again on CD38; plus GT Apeiron’s launch; BiomX, Aimmune, Keytruda

Genmab, Janssen partner on next-gen CD38 mAb Genmab A/S (CSE:GEN; Pink:GMXAY) granted Janssen Biotech Inc. an option to HexaBody-CD38, building on the companies' collaboration on multiple myeloma CD38 mAb Darzalex daratumumab. Genmab will fund R&D...
01:50 , May 10, 2019 |  BC Innovations  |  Targets & Mechanisms

The tumor microbiome emerges as a new source of translational opportunities

While the gut microbiome has attracted wide attention for its influence on anti-tumor immunity, a growing body of research suggests microbes living in the tumor itself may play even broader roles in cancer. At least...
12:47 , Mar 14, 2019 |  BC Innovations  |  Translation in Brief

Bacteriophages: double-edged swords

Utah researchers have shown bacteriophage-host immune interactions can trigger adverse immune responses in GI diseases, a factor phage companies may need to take into account. Phage researchers have long thought mammalian host immunity recognizes the...
14:36 , Mar 5, 2019 |  BC Extra  |  Financial News

First close for Seventure's new microbiome fund

Seventure Partners announced the first close of its second microbiome-focused health fund and is targeting a €200 million ($226.9 million) final raise. Seventure's Isabelle de Cremoux said the VC has raised more than half of...
20:08 , Mar 1, 2019 |  BC Week In Review  |  Financial News

Seventure leads Axial's $25M series B

Axial Biotherapeutics Inc. (Boston, Mass.) raised a $25 million series B led by Seventure Partners on the back of its Parkinson's disease and autism microbiome programs. Existing investors Longwood Fund, Domain Associates and Heritage Medical...
13:00 , Feb 27, 2019 |  BC Extra  |  Financial News

Seventure leads Axial's $25M series B

Axial Biotherapeutics Inc. (Boston, Mass.) raised a $25 million series B led by Seventure Partners on the back of its Parkinson's disease and autism microbiome programs. Existing investors Longwood Fund, Domain Associates and Heritage Medical...